Sarepta Therapeutics, Inc. (SRPT)

Market Cap	1.85B -2.1%
Revenue (ttm)	1.97B -20.4%
Net Income	-136.73M
EPS	-1.32
Shares Out	105.63M
PE Ratio	n/a
Forward PE	42.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,609,944
Open	17.75
Previous Close	17.57
Day's Range	17.21 - 17.76
52-Week Range	14.68 - 25.32
Beta	0.38
Analysts	Hold
Price Target	21.73 (+24.17%)
Est. Earnings	Nov 2, 2026

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 835
• Stock Exchange: Nasdaq
• Ticker Symbol: SRPT
• Website: https://www.sarepta.com

Analyst Summary

According to 24 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $21.73, which is an increase of 24.17% from the latest price.

Price Target

$21.73

(24.17% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 3, 2026

Data Sources Report a data error